BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34469238)

  • 21. Predicting amplification of
    Giwa A; Rossouw SC; Fatai A; Gamieldien J; Christoffels A; Bendou H
    Future Oncol; 2021 Dec; 17(34):4769-4783. PubMed ID: 34751044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
    Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
    BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PRAF2 stimulates cell proliferation and migration and predicts poor prognosis in neuroblastoma.
    Yco LP; Geerts D; Koster J; Bachmann AS
    Int J Oncol; 2013 Apr; 42(4):1408-16. PubMed ID: 23440329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical expressions of Cap43 and Mina53 proteins in neuroblastoma.
    Fukahori S; Yano H; Tsuneoka M; Tanaka Y; Yagi M; Kuwano M; Tajiri T; Taguchi T; Tsuneyoshi M; Kojiro M
    J Pediatr Surg; 2007 Nov; 42(11):1831-40. PubMed ID: 18022432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
    Alaminos M; Gerald WL; Cheung NK
    Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project.
    Mossé YP; Deyell RJ; Berthold F; Nagakawara A; Ambros PF; Monclair T; Cohn SL; Pearson AD; London WB; Matthay KK
    Pediatr Blood Cancer; 2014 Apr; 61(4):627-35. PubMed ID: 24038992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endoglin (CD 105) as a potential prognostic factor in neuroblastoma.
    Ćavar S; Jelašić D; Seiwerth S; Milošević M; Hutinec Z; Mišić M
    Pediatr Blood Cancer; 2015 May; 62(5):770-5. PubMed ID: 25683142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform.
    Cattelani S; Ferrari-Amorotti G; Galavotti S; Defferrari R; Tanno B; Cialfi S; Vergalli J; Fragliasso V; Guerzoni C; Manzotti G; Soliera AR; Menin C; Bertorelle R; McDowell HP; Inserra A; Belli ML; Varesio L; Tweddle D; Tonini GP; Altavista P; Dominici C; Raschellà G; Calabretta B
    Neoplasia; 2012 Jul; 14(7):634-43. PubMed ID: 22904680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
    Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
    Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblastoma.
    Nozato M; Kaneko S; Nakagawara A; Komuro H
    Int J Oncol; 2013 Jan; 42(1):134-40. PubMed ID: 23135478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
    Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
    J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.
    Melaiu O; Mina M; Chierici M; Boldrini R; Jurman G; Romania P; D'Alicandro V; Benedetti MC; Castellano A; Liu T; Furlanello C; Locatelli F; Fruci D
    Clin Cancer Res; 2017 Aug; 23(15):4462-4472. PubMed ID: 28270499
    [No Abstract]   [Full Text] [Related]  

  • 35. Stable knockdown of MYCN by lentivirus-based RNAi inhibits human neuroblastoma cells growth in vitro and in vivo.
    Jiang R; Xue S; Jin Z
    Biochem Biophys Res Commun; 2011 Jul; 410(2):364-70. PubMed ID: 21683062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low NDRG1 mRNA expression predicts a poor prognosis in neuroblastoma patients.
    Matsushita K; Uchida K; Saigusa S; Ide S; Hashimoto K; Koike Y; Otake K; Inoue M; Tanaka K; Kusunoki M
    Pediatr Surg Int; 2013 Apr; 29(4):363-8. PubMed ID: 23296375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic roles of and correlation between
    Chang HH; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Hsu WM; Jeng YM; Jou ST
    J Clin Pathol; 2020 Mar; 73(3):154-161. PubMed ID: 31542727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
    Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
    Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma.
    Ackermann S; Kocak H; Hero B; Ehemann V; Kahlert Y; Oberthuer A; Roels F; Theißen J; Odenthal M; Berthold F; Fischer M
    BMC Cancer; 2014 Nov; 14():840. PubMed ID: 25406647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
    Hallett RM; Seong AB; Kaplan DR; Irwin MS
    Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.